Automotive Anti-Pinch Power Window System Market to Reach $3,611.2 Million by 2023     |    IoT Market in Structure Monitoring to reach $235.3 billion by 2022     |    Electric Scooter and Motorcycle Market to Reach $22,192 million by 2025
P&S Market Research - A market research firm

Small Lymphocytic Lymphoma Therapeutics Pipeline Analysis

P&S Market Research-Small Lymphocytic Lymphoma Therapeutics Pipeline Analysis report

Small Lymphocytic Lymphoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS10960
Available Format: pdf

The rising prevalence of small lymphocytic lymphoma is responsible for the upsurge in research and development of therapeutics that can control progression of the disease, and in turn lead to discovery of new targets that would assist in curing cancer. Increasing adoption of unhealthy lifestyle, unchecked use of pesticides in cultivating crops and fruits along with intake of unhygienic food items causes virus infection such as Hepatitis C and Epstein-Barr virus, which may trigger the incidence of small lymphocytic lymphoma. Therefore, the therapeutic pipeline of small lymphocytic lymphoma is increasing in consequent manner. Consequently, increase in healthcare awareness among consumers is further supplementing growth of small lymphocytic lymphoma therapeutics pipeline

Small lymphocytic lymphoma is a sort of non-Hodgkin lymphoma, which generally affects the B-lymphocytes of the immune system that are present in the lymphoid tissue such as tonsils and spleen, and lymph nodes. However, small lymphocytic lymphoma has many similarities with chronic lymphocytic leukaemia, which acts on the B-lymphocytes that are present in the bone marrow and blood. The observed symptoms of small lymphocytic lymphoma are loss of appetite, night sweats, fever, fatigue, weight loss, etc.

In October 2016, Janssen Research & Development, LLC started a Phase II study of the combination of Ibrutinib, which is bruton’s tyrosine kinase (BTK) inhibitor; and Venetoclax, which is a BCL-2 inhibitor and an antiapoptotic protein, in subjects undergoing the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. This study is expected to be completed by September 2021. In December 2013, Verastem Inc., started a Phase III extension study of Duvelisib and Ofatumumab in patients suffering from chronic lymphocytic leukemia/ small lymphocytic lymphoma, previously enrolled in the study IPI-145-07. This study is expected to be completed by December 2018. In January 2017, Genentech Inc., started a Phase II study of combination of drugs – Atezolizumab, with Obinutuzumab and Ibrutinib, for the treatment of small lymphocytic lymphoma. This study is expected to be completed by January 2021.

In June 2016, Infinity Pharmaceuticals Inc., had stated that AbbVie Inc. has exercised its right to end its collaboration with Infinity to develop and commercialize Duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. With the termination of this agreement, Infinity Pharmaceuticals Inc. has regained worldwide rights of Duvelisib and neither Infinity nor AbbVie Inc. have any future financial obligations to the other party. Duvelisib is an investigational dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, two proteins that are known to help support the growth and survival of malignant B-cells. In July 2013, Janssen Research & Development, LLC submitted a new drug application for ibrutinib, to the U.S. Food and Drug Administration (FDA), for its use in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and for its use in the treatment of previously treated patients with mantle cell lymphoma (MCL). Ibrutinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor being jointly developed by Janssen and Pharmacyclics Inc. for the treatment of B-cell malignancies.

Some of the companies having a pipeline of small lymphocytic lymphoma therapeutics include Janssen Research & Development, LLC, Boehringer Ingelheim GmbH, Verastem, Inc., Celgene Corporation, Shanghai Zhangjiang Biotechnology Limited Company, TG Therapeutics, Inc.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

3250
Group License

Group License authorizes access of the publication upto 5 users.

4000
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

7750
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment